Literature DB >> 18390083

Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers.

T Küçük1, K Ertan.   

Abstract

OBJECTIVE: To compare the efficacy of three progestin regimens in perimenopausal menorrhagia.
DESIGN: One hundred thirty-two women with menorrhagia were included in this prospective, randomized, comparative trial. Women were randomized to three groups of 44 in each, either to get a single shot of depot medroxyprogesterone acetate, intramuscularly (Group 1), or medroxyprogesterone acetate in a daily dose of 5 mg orally (Group 2), or the levonorgestrel releasing intrauterine system (LNG-IUS) (Group 3). The Mann-Whitney U-test was applied to compare independent groups.
RESULTS: Pictorial blood loss assessment chart (PBAC) score, the duration of bleeding and mean hemoglobin level were improved in all groups. Comparing the groups we noted that for the PBAC, there was no statistically significant difference between groups 1 and 2, while group 3 was superior to both groups 1 and 2 (p < 0.05 and p < 0.05, respectively). Mean duration of menstruation showed no differences among the groups. Hemoglobin levels were no statistically significant differences between groups 1 and 2, while group 3 was superior to both groups 1 and 2 (p < 0.05 and p < 0.05, respectively).
CONCLUSION: The efficacies of oral and intramuscular medroxyprogesterone acetate in the treatment of menorrhagia were comparable each other, however, the efficacy of LNG-IUS was superior to both.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390083

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  9 in total

Review 1.  The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.

Authors:  Andrew M Kaunitz; Pirjo Inki
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

2.  Cyclical progestogens for heavy menstrual bleeding.

Authors:  Magdalena Bofill Rodriguez; Anne Lethaby; Cindy Low; Iain T Cameron
Journal:  Cochrane Database Syst Rev       Date:  2019-08-14

Review 3.  Contraception in women over 40 years of age.

Authors:  Rebecca H Allen; Carrie A Cwiak; Andrew M Kaunitz
Journal:  CMAJ       Date:  2013-03-04       Impact factor: 8.262

Review 4.  Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-11-01

5.  Medroxyprogesterone Acetate for Abnormal Uterine Bleeding Due to Ovulatory Dysfunction: The Effect of 2 Different-Duration Regimens.

Authors:  Rukiye Ada Bender
Journal:  Med Sci Monit       Date:  2022-06-24

Review 6.  Contraception During Perimenopause: Practical Guidance.

Authors:  Giovanni Grandi; Pierluigi Di Vinci; Alice Sgandurra; Lia Feliciello; Francesca Monari; Fabio Facchinetti
Journal:  Int J Womens Health       Date:  2022-07-15

7.  Progestogen-releasing intrauterine systems for heavy menstrual bleeding.

Authors:  Magdalena Bofill Rodriguez; Anne Lethaby; Vanessa Jordan
Journal:  Cochrane Database Syst Rev       Date:  2020-06-12

8.  Impact of a new levonorgestrel intrauterine system, Levosert(®), on heavy menstrual bleeding: results of a one-year randomised controlled trial.

Authors:  Marie Mawet; Fabrice Nollevaux; Dominique Nizet; Fabienne Wijzen; Valérie Gordenne; Niso Tasev; Dimitrije Segedi; Bogdan Marinescu; Andreea Enache; Vadim Parhomenko; Francis Frankenne; Jean-Michel Foidart
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-03-26       Impact factor: 1.848

Review 9.  Levonorgestrel-releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta-analysis.

Authors:  Jin Qiu; Jiajing Cheng; Qingying Wang; Jie Hua
Journal:  Med Sci Monit       Date:  2014-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.